C. Robin Ganellin
Charon Robin Ganellin (born January 25, 1934 in London ) is a British chemist who is co-developer of cimetidine .
Ganellin studied at Queen Mary College of London University with the Bachelor Accounts in chemistry and doctorate in organic chemistry at Michael Dewar in 1958 for research on tropylium . He then went to Smith, Kline and French in pharmaceutical research. In 1960 he spent a year at the Massachusetts Institute of Technology in Arthur C. Cope , where he first direct optical resolution of chiral olefins using platinum - complexes achieved. In 1966 he headed a research group at Smith-Kline-French that developed H₂-receptor antagonists (cimetidine) in collaboration with James Whyte Black and the Smith-Kline-French chemists Graham J. Durant (* 1934) and John C. Emmett . The drug was introduced in the UK in 1976 (as Tagamet) and was so successful in treating gastric ulcers that it was given blockbuster status.
Ganellin also continued to research the pharmacology of histamine receptors and became Vice President for Research at Smith-Kline-French in their Welwyn site and from 1986 Professor of Medicinal Chemistry at University College London .
He was inducted into the National Inventors Hall of Fame and was awarded the 2004 Nauta Prize. He is a Fellow of the Royal Society and received a D. Sc. of the University of London. He holds over 160 patents.
Web links
Individual evidence
- ^ Biographical data, publications and academic family tree of C. Robin Ganellin at academictree.org, accessed on February 7, 2018.
| personal data | |
|---|---|
| SURNAME | Ganellin, C. Robin |
| ALTERNATIVE NAMES | Ganellin, Charon Robin (full name) |
| BRIEF DESCRIPTION | British chemist |
| DATE OF BIRTH | January 25, 1934 |
| PLACE OF BIRTH | London |